Short- and long-term effects of imatinib in patients hospitalised for COVID-19 infection: A randomised controlled trial

• DOI: 10.1101/2024.02.02.24302227
• Publication Date: 2024-02-06T23:25:10Z
• Authors: Alex L. E. Halme; Sanna Laakkonen; Jarno Rutanen; Olli P. O. Nevala...; Marjatta Sinisalo; Saana Horstia; Jussi M. J. Mustonen; Negar Pourjamal; Aija Vanhanen; Solidarity Finlan...; Tuomas Rosberg; Andreas Renner; Markus Perola; Erja-Leena Paukkeri; Riitta-Liisa Pato...; Seppo Parkkila; Juuso Paajanen; Taina Nykänen; Jarkko Mäntylä; Marjukka Myllärniemi; Tiina Mattila; Maarit Leinonen; Alvar Külmäsu; Pauliina Kuutti; Ilari Kuitunen; Hanna-Riikka Kreivi; Tuomas P. Kilpelä...; Heikki Kauma; Ilkka E. J. Kalliala; Petrus Järvinen; Riina Hankkio; Taina Hammarén; Thijs Feuth; Hanna Ansakorpi; Riikka Ala-Karvia; Gordon H. Guyatt; Kari A. O. Tikkinen

Abstract We report the short- and long-term results of SOLIDARITY Finland on mortality other patient-important outcomes in patients hospitalised for COVID-19. Between 08/2021 03/2023, we randomised 156 15 hospitals. In imatinib group, 7.2% had died at 30 days 13.3% 1 year standard care group 4.1% 8.3% (adjusted HR 1.09, 95% CI 0.23–5.07). a meta-analysis trials versus (n=732), allocation to was associated with risk ratio 0.73 (95% 0.32–1.63). At 1-year, self-reported recovery occurred 79.0% 88.3% (RR 0.91, 0.78-1.06). Of 21 potential long COVID symptoms, often reported moderate or major bother from fatigue (24%), sleeping problems (19%) memory difficulties (17%). found no convincing difference between groups quality life symptom outcomes. The evidence raises serious doubts regarding benefit reducing mortality, improving recovery, preventing symptoms when given